Choosing biologic therapy in children with severe asthma

Area of Science:

• Pediatric Pulmonology
• Immunology
• Pharmacology

Background:

• Omalizumab, targeting IgE, was the first biologic for severe asthma in 2003.
• Several new biologics targeting specific inflammatory pathways (IL-5, IL-4/IL-13, TSLP) are now available for pediatric severe asthma.
• The expanding biologic portfolio presents challenges in identifying patient endotypes and response criteria.

Purpose of the Study:

• To summarize phase 3 trial findings for biologics in pediatric severe asthma.
• To discuss practical considerations for individualizing biologic therapy in children and adolescents.
• To propose an algorithm for initiating biologic treatments in this population.

Main Methods:

• Review of phase 3 clinical trial data for approved biologics.
• Discussion of clinical practice considerations for biologic selection.
• Development of a proposed initiation algorithm based on asthma endotype.

Main Results:

• Biologics targeting diverse pathways (anti-IgE, anti-IL-5, anti-IL-5R, anti-IL-4/13R, anti-TSLP) have demonstrated efficacy in pediatric severe asthma.
• Accurate endotyping and phenotyping are crucial for optimal biologic selection.
• Phase 3 trials provide evidence for treatment response and safety profiles.

Conclusions:

• The growing number of biologics requires careful patient selection based on specific inflammatory profiles.
• An algorithmic approach can guide clinicians in initiating appropriate biologic therapy for children and adolescents with severe asthma.
• Personalized medicine strategies are essential for maximizing treatment benefits in pediatric severe asthma.